<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477957</url>
  </required_header>
  <id_info>
    <org_study_id>BARIA-DDZ</org_study_id>
    <nct_id>NCT01477957</nct_id>
  </id_info>
  <brief_title>The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism</brief_title>
  <acronym>BARIA-DDZ</acronym>
  <official_title>Assessment of the Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dep.of General-, Visceral- and Pediatric Surgery, HHU, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dep.for Metabolic Diseases, HHU, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        1. To explore to what extent insulin sensitivity, energy metabolism and ectopic lipid&#xD;
           storage can be improved by bariatric surgery&#xD;
&#xD;
        2. To explore to what extent hepatic and muscular disorders of energy metabolism occur in&#xD;
           patients with obesity (degree 2-3)&#xD;
&#xD;
        3. To explore whether the steato liver occurring in patients with obesity (degree 2-3) is&#xD;
           associated with the degree of liver inflammation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance strongly relates to ectopic lipid deposition in skeletal muscle and the&#xD;
      liver, which correlate with insulin resistance. Lipid metabolites accumulating in skeletal&#xD;
      muscle and the liver are thought to impair insulin signalling and thereby reduce glucose&#xD;
      uptake and glycogen storage. Insulin resistant humans frequently present with decreased&#xD;
      mitochondrial function in skeletal muscle which might contribute to lipid accumulation and&#xD;
      the development of insulin resistance. Non-alcoholic liver disease (NAFLD) comprise fatty&#xD;
      liver, steatohepatitis and cirrhosis. NAFLD correlate with insulin resistance increased risk&#xD;
      for cardiovascular diseases, type 2 diabetes and hepatocellular. The mechanisms leading from&#xD;
      fatty liver to steatohepatitis and insulin resistance in the liver are yet unclear. Bariatric&#xD;
      surgery relates to surgery for the reduction of body weight. Bariatric surgery frequently&#xD;
      leads to normalization of glucose tolerance in previously diabetic humans even before the&#xD;
      onset of body weight reduction. The underlying mechanisms are yet unclear. In this study we&#xD;
      aim to explore the mechanisms underlying the onset of insulin resistance and steatohepatitis&#xD;
      in patients with fatty liver and to identify the mechanisms leading to improved glucose&#xD;
      tolerance in humans after bariatric surgery. We test the following hypotheses: increased&#xD;
      lipid availability leads to (i) increased lipid oxidation and oxidative stress (ii)&#xD;
      accumulation of lipid metabolites that impair insulin signalling (iii) bariatric surgery&#xD;
      improves insulin sensitivity by increasing lipid oxidation.&#xD;
&#xD;
      This study will contribute to the understanding of NAFLD and will help to identify new&#xD;
      targets for the therapy of diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy metabolism</measure>
    <time_frame>5 years</time_frame>
    <description>whole body substrate oxidation, ex vivo mitochondrial function via measurement of high resolution respirometry and in vivo mitochondrial function via measurement of ATP production</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>5 years</time_frame>
    <description>body weight and body composition before and after bariatric surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>5 years</time_frame>
    <description>Whole body glucose uptake and endogenous glucose production as measure of skeletal muscle and hepatic insulin sensitivity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bariatric surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>biliopancreatic diversion, gastric banding, gastric sleeve resection</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>bariatric surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 20 years- ≤ 70 years&#xD;
&#xD;
          -  BMI 20- 25 kg/m 2 normal- weight group&#xD;
&#xD;
          -  BMI 35- 39,9 kg/m 2 (Obesity grade 2)&#xD;
&#xD;
          -  BMI &gt;40 kg/m 2 (Obesity grade 3)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness 2 weeks before start of examination&#xD;
&#xD;
          -  Autoimmune or Immune disorder diseases (Leukozyten &lt; 5000/µl&#xD;
&#xD;
          -  Renal insufficiency (Kreatin &gt; 1,5 mg/dl)&#xD;
&#xD;
          -  Heart disease, condition after heart attack&#xD;
&#xD;
          -  Anemia (Hb &lt;12g/l, controlled before every day of examination) or blood donations&#xD;
             4weeks before examination.&#xD;
&#xD;
          -  Participation in another trial within the last 2 weeks&#xD;
&#xD;
          -  Pharmacological- immunotherapy (Cortisol, Antihistaminika, ASS)&#xD;
&#xD;
          -  Thyroid disorders&#xD;
&#xD;
          -  Glitazone Therapy&#xD;
&#xD;
          -  Pregnancy, Lactation, Menstruation&#xD;
&#xD;
          -  Smoking cigarettes, Alcohol- and drug abuse&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Risk for/ or diagnosed HIV/ AIDS or Hepatitis B/C&#xD;
&#xD;
          -  Liver disease, which are not caused by non- alcoholic steato- hepatitis&#xD;
&#xD;
          -  Working on night shifts or irregular rhythm of night- day&#xD;
&#xD;
          -  Impaired wound healing or clotting disorders&#xD;
&#xD;
          -  Allergic reaction to local anesthetics&#xD;
&#xD;
          -  Malignant cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DDZ (Deutsches Diabetes Zentrum)</name>
      <address>
        <city>Düsseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Roden, MD</last_name>
      <phone>49(0) 2 11-33 82-201</phone>
      <email>michael.roden@ddz.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Kahl, MD</last_name>
      <phone>0211/3382-698</phone>
      <email>sabine.kahl@ddz.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://ddz.de/studien/baria-ddz-studie/</url>
    <description>Homepage</description>
  </link>
  <results_reference>
    <citation>Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoefel WT, Schlensak M, Roden M. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015 May 5;21(5):739-46. doi: 10.1016/j.cmet.2015.04.004.</citation>
    <PMID>25955209</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Dr PhD</investigator_title>
  </responsible_party>
  <keyword>weight loss after bariatric surgery</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

